Leerink Swan Boosts Numbers on Amgen (AMGN)

Biotechnology medicines company Amgen, Inc. (AMGN) had its earnings estimates and price target raised by analysts at Leerink Swan on Wednesday, as the company’s T-VEC product continues to perform well in clinical studies.

The analysts maintain a “Market Perform” rating on AMGN and now see shares reaching $99. This target suggests a 7% upside to Tuesday’s closing price of $92.40.

Amgen shares were up $1.81, or +1.92%, during morning trading on Wednesday. The stock is up +39.95% over the past twelve months.

The Bottom Line
Shares of Amgen (AMGN) have a dividend yield of 2.00% based on Wednesday’s intraday trading price of $94.21 and the company’s annualized dividend payout of $1.88 per share.

Amgen, Inc. (AMGN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here